Estimating the Effects of Consolidating Drugs under Part D or Part B

A recent report by Acumen, LLC, finds that consolidating Part B and Part D drug benefits would reduce Medicare’s total payments by $150 million, which is 0.4% percent of total Part D drug costs.

You might also be interested in:

Study: Moving Some Plans to Part D Could Cut Spending, but Not… January 17, 2019
2018 Specialty Drug Trends February 4, 2019
Could Competitive Medicare Advantage Bidding Drive Down Costs? December 17, 2018
PwC Report: IPI Would Cut Pharma Profits, Boost Competition January 30, 2019
Report Finds Rising Costs, Variable Coverage July 29, 2018
HealthCare Partners Holding OKs $270M Settlement Over False… October 3, 2018
Survey: 42% See Value-Based Reimbursement Models Becoming… November 16, 2018